<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506606</url>
  </required_header>
  <id_info>
    <org_study_id>E3343-R</org_study_id>
    <nct_id>NCT04506606</nct_id>
  </id_info>
  <brief_title>Cardiac Rehab Effects in HFpEF</brief_title>
  <official_title>Efficacy of Exercise Training in Patients With HFpEF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research in Veterans with heart failure with preserved ejection fraction (HFpEF) will&#xD;
      provide new information on the mechanisms determining the patients' exercise intolerance and&#xD;
      the efficacy of regular physical activity to improve this shortcoming by alleviating the&#xD;
      patients' neurocirculatory abnormalities. Specifically, the investigators will focus on the&#xD;
      role of nerves originating in working limb muscles in determining the patients' exercise&#xD;
      intolerance and compromised fatigue resistance before and after a chronic exercise&#xD;
      intervention. By focusing on a specific mechanism, this project will evaluate the validity of&#xD;
      exercise as an alternative treatment strategy with the overall purpose of improving the&#xD;
      quality of life of Veterans with HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with heart failure with preserved ejection fraction (HFpEF) are characterized by&#xD;
      exercise intolerance and premature fatigue during physical activity. An abnormal exercise&#xD;
      pressor reflex mediated by neural feedback from mechano- and/or metabosensitive group III and&#xD;
      IV muscle afferents may contribute to these debilitating symptoms. However, little is known&#xD;
      about the role and relative contribution of group III/IV afferents in circulatory control and&#xD;
      fatigue development in patients with HFpEF. By studying both patients with HFpEF and&#xD;
      well-matched controls, the investigators will evaluate the contribution of these muscle&#xD;
      afferents to circulatory control and fatigue development, factors recognized to be major&#xD;
      contributors to exercise intolerance. The investigators will use lumbar intrathecal fentanyl&#xD;
      to block the central projection of group III/IV muscle afferents during voluntary and passive&#xD;
      exercise (no concomitant effect on feedforward drive). This proven approach will enable us to&#xD;
      evaluate, and distinguish between, the effects of group III and IV muscle afferents on&#xD;
      central and peripheral hemodynamics during exercise, the exercise-induced development of&#xD;
      central and peripheral fatigue (femoral nerve stimulation techniques), and on exercise&#xD;
      tolerance. The investigators will also study muscle morphometry, baroreflex and chemoreflex&#xD;
      sensitivity, and investigate intramuscular metabolic changes of the quadriceps during&#xD;
      exercise using 31phosphorus magnetic resonance spectroscopy to evaluate disease-related&#xD;
      alterations in cardiovascular reflex sensitivity and intrinsic muscle characteristics as a&#xD;
      potential factor determining alterations in circulatory control and fatigue resistance in&#xD;
      patients with HFpEF. Finally, the investigators will repeat these studies after a supervised&#xD;
      12-week knee-extension exercise training program, allowing us to investigate the effect of&#xD;
      chronic exercise on the role of group III/IV muscle afferents in the hemodynamic response to&#xD;
      exercise, the development of fatigue, and, ultimately, exercise tolerance. If this project&#xD;
      confirms a significant contribution of group III/IV muscle afferents to the exercise&#xD;
      intolerance exhibited by patients with HFpEF, and that chronic exercise can alleviate these&#xD;
      impairments, the proposed work will provide the scientific basis for a paradigm shift in the&#xD;
      treatment of this growing population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>femoral blood flow</measure>
    <time_frame>1 hour</time_frame>
    <description>Quantifying femoral blood flow during exercise with and without afferent blockade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>femoral blood flow</measure>
    <time_frame>12 weeks</time_frame>
    <description>Impact of cardiac rehab on the influence of afferent blockade on femoral blood flow</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Afferent effect on hemodynamics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate impact of group III/IV muscle afferents on femoral blood flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afferent effect on fatigue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of cardiac rehab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Afferent block</intervention_name>
    <description>Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents</description>
    <arm_group_label>Afferent effect on fatigue</arm_group_label>
    <arm_group_label>Afferent effect on hemodynamics</arm_group_label>
    <arm_group_label>Effect of cardiac rehab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  heart failure with preserved ejection fraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  heart failure with reduced ejection fraction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Amann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Salt Lake City Health Care System, Salt Lake City, UT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Misti R Seppi, MBA BS AAS</last_name>
    <phone>(801) 582-1565</phone>
    <phone_ext>4860</phone_ext>
    <email>Misti.Seppi@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tabitha Randall, MS</last_name>
    <phone>(801) 582-1565</phone>
    <phone_ext>4855</phone_ext>
    <email>tabitha.randall@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Misti R Seppi, MBA BS AAS</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>4860</phone_ext>
      <email>Misti.Seppi@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Tabitha Randall, MS</last_name>
      <phone>(801) 582-1565</phone>
      <phone_ext>4855</phone_ext>
      <email>tabitha.randall@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Amann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

